Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Prostate Tumor Monoclonal Antibody (YPMA-2)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA1-21390
产品规格
种属反应
Human
宿主/亚型
Mouse
/ IgG3
分类
Monoclonal
类型
Antibody
克隆号
YPMA-2
抗原
Membrane protein extracted from human prostate mucin tissues.
偶联物
形式
Liquid
浓度
1 mg/mL
纯化类型
Protein G
保存液
PBS, pH 7.2
内含物
no preservative
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
RRID
产品详细信息
This antibody reacts specifically with prostate mucin antigen. It does not react with fetal or benign prostate specimens, non-prostate carcinomas and normal human tissues.
靶标信息
Prostate tumors, primarily arising as prostate cancer, are one of the most common malignancies in men. Prostate cancer develops in the prostate gland, which is responsible for producing seminal fluid. The onset of prostate cancer is often asymptomatic in its early stages, but as the disease progresses, symptoms such as difficulty in urination, pelvic pain, and blood in urine or semen may appear. Prostate cancer is typically a slow-growing tumor; however, some forms can be aggressive and metastasize to other parts of the body, particularly the bones and lymph nodes. The development of prostate cancer is influenced by genetic, environmental, and hormonal factors, with age being a significant risk factor. Diagnosis is commonly achieved through digital rectal exams (DRE), prostate-specific antigen (PSA) testing, and biopsy. Treatment options vary depending on the stage and aggressiveness of the tumor, ranging from active surveillance for low-risk cases to surgery, radiation therapy, hormonal therapy, and chemotherapy for more advanced stages.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
